Este ítem es privado
Immune dysfunction, minimal residual disease and patient outcome in non-metastatic cancer; could modulation of immune function improve outcome
Fecha
2021-02
Autores
Murray, Nigel P
Profe guía
Perfil ORCID
Título de la revista
ISSN de la revista
Título del volumen
Editor
Future Science Group
ISBN
ISSN
1479-6694
ISSNe
DOI
Resumen
Immune modulation by the primary tumour, by surgical resection and adjuvant treatment combined with the biological characteristics of the tumour cell subpopulations will determine patient outcome. In patients with mRD, combined low dose metronomic chemotherapy may improve immune function and the effect of combination therapy to eliminate MRD or may be sufficient to maintain disseminated tumour cells in a dormant state prolonging disease free survival with minimal side effects. the ability to measure and phenotype subtypes of MRD provides an early detection of disease response or progression and determining the most adequate therapy. In asymptomatic patients lower toxicity compared with conventional chemotherapy is important
Descripción
Lugar de Publicación
Sponsorship
Citación
Future Oncol 2021; 17: 1571-1575 http://doi.org:10.2217/fon-2020-1259